Sumitomo Pharma KK

4506

Equity

ISIN JP3495000006 / Valor 761695

Tokyo Stock Exchange (2024-11-19)

JPY 605.00+3.42%

Sumitomo Pharma KK
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Sumitomo Pharma KK is a global pharmaceutical company focused on innovative research and development to enhance healthcare and improve the quality of life. The company prioritizes Psychiatry & Neurology and Oncology, developing pharmaceutical products, regenerative medicine, cell therapy, and non-pharmaceutical solutions. Sumitomo Pharma aims to become a Global Specialized Player by 2033, leveraging its assets to deliver value to patients. The company has established robust business foundations in Japan, the United States, and China, with local headquarters, sales, and R&D functions. Additionally, it promotes collaboration with partners in Europe and other regions and utilizes healthcare technology platforms like DrugOME and Digital Innovation to enhance research success and business returns.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Sumitomo Pharma KK reported a significant increase in revenue for the first quarter of the year ending March 31, 2025. The revenue rose by 19.8% year-on-year, reaching 90.7 billion JPY. This growth was primarily driven by the sales expansion of key products such as ORGOVYX®, MYFEMBREE®, and GEMTESA®.

Core Operating Profit

The core operating profit for Sumitomo Pharma KK saw a substantial improvement in the first quarter of the year ending March 31, 2025. The company reported a core operating profit of -0.9 billion JPY, a significant recovery from the -33.5 billion JPY recorded in the same period the previous year.

Net Profit

Sumitomo Pharma KK achieved a net profit of 15.9 billion JPY for the first quarter of the year ending March 31, 2025. This marks a remarkable turnaround from the net loss of 38.9 billion JPY reported in the same quarter of the previous year, reflecting a positive shift in the company's financial performance.

Profit Before Taxes

For the first quarter of the year ending March 31, 2025, Sumitomo Pharma KK reported a profit before taxes of 17.2 billion JPY. This is a significant improvement compared to the loss of 31.1 billion JPY recorded in the same period the previous year, indicating a strong recovery in the company's profitability.

Dividends

Sumitomo Pharma KK has announced that there will be no dividend payments for the first quarter of the year ending March 31, 2025. The company has maintained its forecast of zero dividends for the entire fiscal year, consistent with its previous announcements.

Summarized from source with an LLMView Source

Key figures

29.0%1Y

-58.8%3Y

-69.8%5Y

Performance

57.0%1Y

43.3%3Y

42.1%5Y

Volatility